 AngioDynamics posted better sales growth in FQ422 as elective procedure counts continue to rebound, but margin pressures continue to weigh significantly. The company is building a sustainable core growth story, with multiple opportunities to gain share and grow addressable markets in thrombectomy, atherectomy, and cancer. 